Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Jan 15;8(1):1498-500.
eCollection 2015.

Treatment of pure red cell aplasia associated with multiple myeloma with biclonal gammopathy using cyclosporine A: a case report

Yali Lv  1 , Wenbin Qian  2
Affiliations
Case Reports

Treatment of pure red cell aplasia associated with multiple myeloma with biclonal gammopathy using cyclosporine A: a case report

Yali Lv et al. Int J Clin Exp Med. .

Abstract

We reported a rare case of pure red cell aplasia in a 44-year-old man with multiple myeloma with biclonal gammophathy (IgG lambda and IgA lambda type) with severe anemia. After treatment with bortezomib, adriamycin, and dexamethasone, the patient achieved very good partial response with disappearance of monoclonal gammopathy. However, his anemia was not significantly improved. Bone marrow analysis revealed selective erythroid hypoplasia. Thus, cyclosporine A was administered, which resulted in a complete recovery from anemia. The present case may provide some insight into the pathogenesis of PRAC and malignant plasma cell disorder.

Keywords: Multiple myeloma; bortezomib; cyclosporine A; pure red cell aplasia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. Serum immunofixation electrophoresis. It shows biclonal gammophthy of IgG lambda and IgA lambda type. B. Photomicrographs of bone marrow aspirate at diagnosis showing infiltration by malignant plasma cells, and absent erythropoiesis (H&E, 40× and 100×). C. Photomicrographs of bone marrow aspirate after treatment with bortezomib (H&E, 40× and 100×). There is an almost complete absence of red-cell precursors.
See this image and copyright information in PMC

References

    1. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142:505–14. - PMC - PubMed
    1. Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87:4831–8. - PubMed
    1. Orchard J, Myint H, Hamblin TJ. A patient with myeloma who still has pure red cell aplasia despite the most intensive immune modulation. Leuk Res. 1997;21:353–4. - PubMed
    1. Sarathy KS, Ramakrishna R, Baig WW, Manoharan A. Acquired pure red cell aplasia in patients with plasma cell neoplasm and long term remission with bortezomib therapy. J Hematol Malig. 2013;3:37–43.
    1. Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. Am Soc Clin Oncol Educ Book. 2014;34:199–203. - PubMed

Publication types